News
ITCI
68.20
-1.35%
-0.93
Where Intra-Cellular Therapies Stands With Analysts
Intra-Cellular Therapies is a biopharmaceutical company that develops drugs for treating diseases of the central nervous system. The company has an average price target of $91.57. 14 analysts have shared their insights on the company over the past three months. The 12-month price targets offer insights with an average of $120.00.
Benzinga · 7h ago
Intra-Cellular Therapies Price Target Raised to $78.00/Share From $75.00 by JP Morgan
Dow Jones · 9h ago
Intra-Cellular Therapies Is Maintained at Overweight by JP Morgan
Dow Jones · 9h ago
JP Morgan Maintains Overweight on Intra-Cellular Therapies, Raises Price Target to $78
Benzinga · 9h ago
Buy Rating Affirmed for Intra-Cellular Therapies with a Raised Price Target Amidst Caplyta’s Promising Outlook in adj MDD Market
TipRanks · 10h ago
U.S. RESEARCH ROUNDUP-Biontech, Honeywell International, Klaviyo
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Biontech, Honeywell International, Klaviyo and NetApp among those. Academy Sports and Outdoors Inc, a maker of sports equipment, cut its target price.
Reuters · 13h ago
INTRA-CELLULAR THERAPIES INC <ITCI.O>: JP MORGAN RAISES TARGET PRICE TO $78 FROM $75
Reuters · 16h ago
Intra-Cellular Therapies (ITCI) Gets a Buy from RBC Capital
TipRanks · 2d ago
Weekly Report: what happened at ITCI last week (0603-0607)?
Weekly Report · 2d ago
Intra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
Intra-Cellular Therapies, Inc. Is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders. Sharon Mates, Ph.D., is scheduled to present at the 45th Annual Goldman Sachs Global Healthcare Conference.
Barchart · 2d ago
34% Of This Intra-Cellular Therapies Insider's Holdings Were Sold
Intra-Cellular Therapies, Inc. Insiders sold US$860k worth of shares in the last year. The biggest single sale was 34% of Mark Neumann's stake in the company. In the last 12 months,  insiders were net sellers of  intra-cellular therapies shares. Intra- cellular Therapies insiders own 2.1% of the company. You can see the insider transactions of  Intra cellular  Therapy in the last year.
Simply Wall St · 06/03 17:53
Weekly Report: what happened at ITCI last week (0527-0531)?
Weekly Report · 06/03 09:24
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Veeva Systems (VEEV), Intra-Cellular Therapies (ITCI) and Phreesia (PHR)
TipRanks · 05/31 10:40
Weekly Report: what happened at ITCI last week (0520-0524)?
Weekly Report · 05/27 09:24
Viking, CRISPR, Intellia among potential M&A targets: Wells Fargo
Wells Fargo released its annual biopharma M&A screen for 2024. The investment bank identified 31 companies in the SMid-cap space that demonstrate a high or medium fit to large-cap pharmaceutical companies. Viking, CRISPR, Intellia among potential acquisition targets for AbbVie and Gilead.
Seeking Alpha · 05/25 14:24
Weekly Report: what happened at ITCI last week (0513-0517)?
Weekly Report · 05/20 09:23
Weekly Report: what happened at ITCI last week (0506-0510)?
Weekly Report · 05/13 09:24
Maintained Buy Rating on ITCI Shares Amidst Strong Caplyta Revenue and Positive MDD Study Outlook
TipRanks · 05/10 06:08
Intra-Cellular Therapies: A Buy Rating on Solid Financials and Promising Drug Development
TipRanks · 05/10 05:34
Buy Rating Affirmed on Intra-Cellular Therapies Amid Strong Sales and Promising Clinical Trials
TipRanks · 05/10 05:18
More
Webull provides a variety of real-time ITCI stock news. You can receive the latest news about Intra-Cellular Therapies through multiple platforms. This information may help you make smarter investment decisions.
About ITCI
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. The Company leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program. ITI-1284 is a deuterated form of lumateperone, a new chemical entity.